

Clinical Trial Protocol

Iranian Registry of Clinical Trials

21 Jul 2026

Evaluation effect of intravenous Hydrocortisone on hyperamylasemia of patients underwent Endoscopic retrograde cholangiopancreatography

Protocol summary

Summary

The aim of this clinical trial was evaluation effect of intravenous hydrocortisone on hyperamylasemia of patients underwent Endoscopic retrograde cholangiopancreatography (ERCP). Inclusion criteria included highness of amylase levels (less than three times normal) before ERCP. Exclusion criteria included current or history of corticosteroid use within 2 weeks ago, developing pancreatitis during the 2 weeks before ERCP and developing chronic pancreatitis. This study that performed on patients underwent ERCP. 90 patients evaluated in two case and control groups, in case group, Ampoule hydrocortisone (manufactured by pharmaceutical Exir) 100 mg will inject intravenously slowly at 0.5-1 hours before ERCP. In control group, 2 cc Normal saline (Placebo) will injected at 0.5-1 hours before ERCP. Amylase levels of patients will be checked at 2 hours after ERCP.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201410236388N6**

Registration date: **2014-12-19, 1393/09/28**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2014-12-19, 1393/09/28

Registrant information

Name

Mohamadhosssein Somi

Name of organization / entity

Tabriz University of Medical Science

Country

Iran (Islamic Republic of)

Phone

+98 41 1336 7499

Email address

somimh@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor of Tabriz University of Medical Sciences

Expected recruitment start date

2013-12-22, 1392/10/01

Expected recruitment end date

2014-11-22, 1393/09/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation effect of intravenous Hydrocortisone on hyperamylasemia of patients underwent Endoscopic retrograde cholangiopancreatography

Public title

Evaluation effect of Hydrocortisone on amylase level of patients underwent Endoscopic retrograde cholangiopancreatography

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria: Highness of Amylase levels (less than three times normal) before ERCP. Exclusion criteria: Developing diabetes; Current or history of corticosteroid use within 2 weeks ago; Developing pancreatitis during the 2 weeks before ERCP; Developing chronic pancreatitis

Age

No age limit

Gender

Both

Phase

N/A

Groups that have been masked*No information***Sample size**Target sample size: **90****Randomization (investigator's opinion)**

Randomized

Randomization description**Blinding (investigator's opinion)**

Double blinded

Blinding description**Placebo**

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Tabriz University of Medical Sciences

Street address

Medical Faculty, Tabriz University of Medical Sciences, Daneshgah Ave, Tabriz

City

Tabriz

Postal code**Approval date**

2010-04-28, 1389/02/08

Ethics committee reference number

9318

Health conditions studied**1****Description of health condition studied**

Acute pancreatitis

ICD-10 code

K85.9

ICD-10 code description

Disease of pancreas, unspecified

Primary outcomes**1****Description**

Serum Amylase

Timepoint

2 hours after ERCP

Method of measurement

Check by Laboratory

Secondary outcomes

empty

Intervention groups**1****Description**

Case Group: injection Ampoule hydrocortisone (manufactured by pharmaceutical Exir) 100 mg intravenously at 0.5-1 hours before ERCP

Category

Treatment - Drugs

2**Description**

Control Group: Injection of 2 cc Normal saline (Placebo) at 0.5-1 hours before ERCP

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Tabriz Imam Reza Hospita

Full name of responsible person**Street address****City**

Tabriz

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Vice chancellor of Tabriz University of Medical Sciences

Full name of responsible person

Mrs. Azari

Street address

Tabriz University of Medical Sciences

City

Tabriz

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Vice chancellor of Tabriz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact

Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Dr. Amin Sadrazar
Position
Resident of Internal Medicine
Other areas of specialty/work
Street address
Tabriz Imam Reza Hospital
City
Tabriz
Postal code
Phone
+98 41 3337 3966
Fax
Email
a_sadrazar@yahoo.com
Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Dr. Amin Sadrazar
Position
Resident of Internal Medicine
Other areas of specialty/work
Street address
Tabriz Imam Reza Hospital
City
Tabriz

Postal code
Phone
+98 41 3337 3966
Fax
Email
a_sadrazar@yahoo.com
Web page address

Person responsible for updating data

Contact

Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Dr. Amin Sadrazar
Position
Resident of Internal Medicine
Other areas of specialty/work
Street address
Tabriz Imam Reza Hospital
City
Tabriz
Postal code
Phone
+98 41 3337 3966
Fax
Email
a_sadrazar@yahoo.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty